
## **Bernard Royer**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3056030/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients. Annals of Surgical Oncology, 2022, 29, 3322-3334.	1.5	3
2	Exposureâ€response analysis of Raltitrexed assessing liver toxicity. British Journal of Clinical Pharmacology, 2021, 87, 1327-1337.	2.4	5
3	Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients. Cancer Chemotherapy and Pharmacology, 2021, 87, 229-239.	2.3	4
4	Population Pharmacokinetics of Palbociclib in a Real-World Situation. Pharmaceuticals, 2021, 14, 181.	3.8	4
5	Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients. Pharmaceutics, 2021, 13, 1708.	4.5	8
6	A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1132, 121844.	2.3	34
7	A simple and fast LC–MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1060, 240-246.	2.3	3
8	Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 156, 199-203.	1.1	4
9	Level of evidence for therapeutic drug monitoring of taxanes. Fundamental and Clinical Pharmacology, 2011, 25, 414-424.	1.9	12
10	Level of evidence for therapeutic drug monitoring for etoposide after oral administration. Fundamental and Clinical Pharmacology, 2011, 25, 277-282.	1.9	5
11	Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study. Anti-Cancer Drugs, 2010, 21, 320-325.	1.4	13
12	An APCI LCâ€MS/MS method for routine determination of capecitabine and its metabolites in human plasma. Journal of Mass Spectrometry, 2010, 45, 670-677.	1.6	29
13	Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative Administration. Clinical Pharmacokinetics, 2009, 48, 169-180.	3.5	11
14	The Authors' Reply. Clinical Pharmacokinetics, 2009, 48, 686-687.	3.5	0
15	Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World Journal of Surgical Oncology, 2009, 7, 14.	1.9	30
16	Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemotherapy and Pharmacology, 2008, 61, 415-421.	2.3	22
17	Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. Anti-Cancer Drugs, 2006, 17, 1211-1217.	1.4	18
18	Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anti-Cancer Drugs, 2005, 16, 1009-1016.	1.4	39